Study on mechanism of interfering with LncRNA expressing to reduce paclitaxel resistance in non-small cell lung cancer cells

JIN Yi; KANG Cong; HE Ping; WANG Dingding; YANG Hailong; CHEN Xiaowei

doi:10.6039/j.issn.1001-0408.2023.12.10

您当前的位置：

首页 >

文章列表页 >

Study on mechanism of interfering with LncRNA expressing to reduce paclitaxel resistance in non-small cell lung cancer cells

更新时间：2025-09-27

- Study on mechanism of interfering with LncRNA expressing to reduce paclitaxel resistance in non-small cell lung cancer cells
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1460-1467(2023)
- 作者机构：
  
  衡水市人民医院胸外科，河北衡水　053000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.12.10
  CLC： R965
- Received：12 November 2022，
  
  Revised：2023-04-03，
  
  Accepted：10 April 2023，
  
  Published：30 June 2023
- 稿件说明：
移动端阅览
靳义,康聪,贺平,等.干扰LncRNA表达减轻非小细胞肺癌细胞对紫杉醇耐药的机制研究[J].中国药房,2023,34(12):1460-1467.

JIN Yi,KANG Cong,HE Ping,et al.Study on mechanism of interfering with LncRNA expressing to reduce paclitaxel resistance in non-small cell lung cancer cells[J].ZHONGGUO YAOFANG,2023,34(12):1460-1467.
靳义,康聪,贺平,等.干扰LncRNA表达减轻非小细胞肺癌细胞对紫杉醇耐药的机制研究[J].中国药房,2023,34(12):1460-1467. DOI： 10.6039/j.issn.1001-0408.2023.12.10.

JIN Yi,KANG Cong,HE Ping,et al.Study on mechanism of interfering with LncRNA expressing to reduce paclitaxel resistance in non-small cell lung cancer cells[J].ZHONGGUO YAOFANG,2023,34(12):1460-1467. DOI： 10.6039/j.issn.1001-0408.2023.12.10.

摘要

目的

研究干扰长链非编码RNA烟酰胺核苷酸转氢酶反义RNA1（LncRNA NNT-AS1）表达减轻非小细胞肺癌（NSCLC）细胞对紫杉醇（TAX）耐药的机制。

方法

构建NSCLC TAX耐药细胞系（A549/TAX），检测正常、亲本、耐药细胞中LncRNA NNT-AS1的表达情况，并验证miR-582-5p与LncRNA NNT-AS1、HMGB2的靶向关系；体外培养A549/TAX细胞，观察单独干扰LncRNA NNT-AS1或同时干扰LncRNA NNT-AS1、miR-582-5p对细胞中LncRNA NNT-AS1、miR-582-5p、HMGB2 mRNA及其蛋白表达以及细胞活力、克隆形成、凋亡的影响；通过裸鼠成瘤实验观察干扰LncRNA NNT-AS1对肿瘤生长及肿瘤组织中miR-582-5p、HMGB2 mRNA及其蛋白表达的影响。

结果

与正常细胞比较，LncRNA NNT-AS1在亲本、耐药细胞中均呈高表达（

＜0.05），且有递增趋势。经验证，miR-582-5p与LncRNA NNT-AS1、HMGB2均存在靶向关系。干扰LncRNA NNT-AS1表达后，A549/TAX细胞中LncRNA NNT-AS1、HMGB2 mRNA及其蛋白的表达水平以及细胞活力、克隆形成数均显著降低，而miR-582-5p的表达水平、细胞凋亡率均显著升高（

＜0.05）；同时干扰miR-582-5p表达可使上述改变得以逆转（

＜0.05）。干扰肿瘤细胞中LncRNA NNT-AS1的表达后，荷瘤裸鼠的肿瘤体积和肿瘤质量均显著降低，miR-582-5p的表达水平显著升高，HMGB2 mRNA及其蛋白的表达水平均显著降低（

＜0.05）。

结论

干扰LncRNA NNT-AS1的表达可靶向上调miR-582-5p的表达并下调HMGB2的表达，进而减轻NSCLC TAX化疗耐药。

Abstract

OBJECTIVE

To study the mechanism of interfering with long non-coding RNA nicotinamide nucleotide transhydrogenase-antisense RNA1 （LncRNA NNT-AS1） expressing to reduce paclitaxel （TAX） resistance in non-small cell lung cancer （NSCLC） cells.

METHODS

NSCLC TAX-resistant cell line （A549/TAX） was constructed， and the expressions of LncRNA NNT-AS1 in normal， parental， and drug-resistant cells were observed. The targeting relationship of microRNA-582-5p （miR-582-5p） with LncRNA NNT-AS1 and high mobility group box2 （HMGB2） was verified. A549/TAX cells were cultured

in vitro

to observe the effects of interfering with LncRNA NNT-AS1 alone or interfering with LncRNA NNT-AS1 and miR-582-5p on the expressions of LncRNA NNT-AS1 and miR-582-5p， the mRNA and protein expressions of HMGB2， cell viability， clone formation and apoptosis. The effects of interfering with LncRNA NNT-AS1 on tumor growth and the expression of miR-582-5p and the mRNA and protein expressions of HMGB2 in tumor tissue were observed in nude mice.

RESULTS

Compared with normal cells， LncRNA NNT-AS1 was highly expressed in parental and drug-resistant cells （

＜0.05）， showing an increasing trend. It was validated that miR-582-5p had a targeting relationship with LncRNA NNT-AS1 and HMGB2. After interfering with the expression of LncRNA NNT-AS1， the expression of LncRNA NNT-AS1 and the mRNA and protein expressions of HMGB2， cell viability and the number of cloned cells in A549/TAX cell， decreased significantly， while the expression of miR-582-5p and the apoptotic rate increased significantly （

＜0.05）； simultaneously int

erfering with the expression of miR-582-5p could reverse above changes （

＜0.05）. Interfering with the expression of LncRNA NNT-AS1 in tumor cell could significantly reduce tumor volume and tumor weight of nude mice bearing tumors； at the same time， the expression of miR-582-5p was up-regulated significantly and the mRNA and protein expressions of HMGB2 were down-regulated significantly （

＜0.05）.

CONCLUSIONS

Interfering with the expression of LncRNA NNT-AS1 may alleviate TAX chemotherapy resistance in NSCLC through targeted up-regulation of miR-582-5p and down-regulation of HMGB2.

关键词

Keywords

references

THAI A A ， SOLOMON B J ， SEQUIST L V ， et al . Lung cancer [J ] . Lancet ， 2021 ， 398 （ 10299 ）： 535 - 554 .

MIN H Y ， LEE H Y . Mechanisms of resistance to chemotherapy in non-small cell lung cancer [J ] . Arch Pharm Res ， 2021 ， 44 （ 2 ）： 146 - 164 .

KANG W B ， JI Y H ， CHENG Y . Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy [J ] . Int J Pharm ， 2021 ， 603 ： 120691 .

LI P P ， LI R G ， HUANG Y Q ， et al . LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability [J ] . Aging ， 2021 ， 13 （ 21 ）： 24171 - 24191 .

SHI C ， REN S J ， ZHAO X D ， et al . lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis [J ] . Pharmacogenomics ， 2022 ， 23 （ 18 ）： 973 - 985 .

TANIUE K ， AKIMITSU N . The functions and unique features of LncRNAs in cancer development and tumorige-nesis [J ] . Int J Mol Sci ， 2021 ， 22 （ 2 ）： 632 .

HE W L ， ZHANG Y Y ， XIA S L . LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis [J ] . Thorac Cancer ， 2020 ， 11 （ 3 ）： 549 - 560 .

张欣萍，史天云，徐方方，等 . LncRNA NNT-AS1通过靶向miR-496调控卵巢癌细胞增殖、迁移及侵袭的分子机制 [J ] . 中国老年学杂志， 2021 ， 41 （ 5 ）： 1071 - 1075 .

CAI Y ， DONG Z Y ， WANG J Y . LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway [J ] . Eur Rev Med Pharmacol Sci ， 2018 ， 22 （ 15 ）： 4879 - 4887 .

WANG L L ， ZHANG M . miR-582-5p is a potential prognostic marker in human non-small cell lung cancer and functions as a tumor suppressor by targeting MAP3K2 [J ] . Eur Rev Med Pharmacol Sci ， 2018 ， 22 （ 22 ）： 7760 - 7767 .

MEI J J ， ZHANG Y ， LU S S ， et al . Long non-coding RNA NNT-AS1 regulates proliferation，apoptosis，inflammation and airway remodeling of chronic obstructive pulmonary disease via targeting miR-582-5p/FBXO11 axis [J ] . Biomedecine Pharmacother ， 2020 ， 129 ： 110326 .

WANG F M ， LUO Y ， ZHANG L ， et al . The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway [J ] . Cancer Gene Ther ， 2022 ， 29 （ 3/4 ）： 292 - 303 .

CÁMARA-QUÍLEZ M ， BARREIRO-ALONSO A ， VIZOSO-VÁZQUEZ Á ， et al . The HMGB1-2 ovarian cancer interactome： the role of HMGB proteins and their interac ting partners MIEN 1 and NOP53 in ovary cancer and drug-response [J ] . Cancers ， 2020 ， 12 （ 9 ）： 2435 .

张汀荣，陆向东，张瑶，等 . CTEN通过TGF-β1促进非小细胞肺癌细胞紫杉醇耐药的作用及机制研究 [J ] . 现代肿瘤医学， 2021 ， 29 （ 12 ）： 2035 - 2040 .

YANG T ， LI H ， CHEN T J ， et al . LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis [J ] . Mol Cells ， 2019 ， 42 （ 3 ）： 270 - 283 .

NI L W ， XU J H ， ZHAO F L ， et al . miR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo [J ] . Eur J Pharmacol ， 2021 ， 899 ： 174054 .

SINGH T ， FATEHI HASSANABAD M ， FATEHI HASSANABAD A . Non-small cell lung cancer：emerging molecular targeted and immunotherapeutic agents [J ] . Biochim Biophys Acta Rev Cancer ， 2021 ， 1876 （ 2 ）： 188636 .

LIU Z J ， LIN H M ， GAN Y ， et al . P16 methylation leads to paclitaxel resistance of advanced non-small cell lung cancer [J ] . J Cancer ， 2019 ， 10 （ 7 ）： 1726 - 1733 .

ZHAO Y ， HONG L . lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-κB signaling pathway [J ] . Cancer Biother Radiopharm ， 2021 ， 36 （ 2 ）： 202 - 210 .

SHEN Q ， JIANG Y . LncRNA NNT-AS1 promotes the proliferation，and invasion of lung cancer cells via regulating miR-129-5p expression [J ] . Biomed Pharmacother ， 2018 ， 105 ： 176 - 181 .

ZHU B W ， MITHEERA V ， FINCH-EDMONDSON M ， et al . miR-582-5p is a tumor suppressor microRNA targeting the hippo-YAP/TAZ signaling pathway in non-small cell lung cancer [J ] . Cancers ， 2021 ， 13 （ 4 ）： 756 .

HU Y F ， SU Y N ， LEI X ， et al . LINC00641/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma [J ] . Sci Rep ， 2020 ， 10 （ 1 ）： 14981 .

WANG W M ， LI L ， ZHAO L . LINC00184 plays an oncogenic role in non-small cell lung cancer via regulation of the miR-524-5p/HMGB2 axis [J ] . J Cell Mol Med ， 2021 ， 25 （ 21 ）： 9927 - 9938 .

LIANG C ， WANG J ， LIU A H ， et al . Tumor promoting long non-coding RNA CASC15 affects HMGB2 expression by sponging miR-582-5p in colorectal cancer [J ] . J Gene Med ， 2022 ， 24 （ 6 ）： e3308 .

PAN T ， XUE M . LncRNA-NNT-AS1 contributes to the progression of glioma by miR-582-5p/EZH2 axis [J ] . Cytotechnology ， 2021 ， 73 （ 3 ）： 473 - 482 .

Views

103

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in the application of physiologically-based pharmacokinetic model in EGFR-TKI precision therapy

Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer

胸腺五肽联合TP方案治疗晚期非小细胞肺癌的成本-效果分析

生脉注射液联合化疗治疗非小细胞肺癌的系统评价

康莱特注射液辅助治疗非小细胞肺癌的疗效观察

Related Author

YU Xian

LI Guoxing

XIANG Qiulin

SHAO Jiaqi

YANG Yingying

NING Lijuan

SHEN Aizong

JI Peng

Related Institution

Phase Ⅰ Clinical Trial Center， the Second Affiliated Hospital of Chongqing Medical University

College of Pharmacy， Chongqing Medical University

Dept. of Pharmacy，the First Affiliated Hospital of University of USTC， Division of Life Sciences and Medicine， Univerisity of Science and Technology of China/Anhui Technology Center for Clinical Comprehensive Evaluation of Drugs

⁰